ClinicalTrials.Veeva

Menu

Bone Toxicity Following Pelvic Radiotherapy (RadBone)

T

The Christie NHS Foundation Trust

Status

Active, not recruiting

Conditions

Radiotherapy Side Effect
Fracture
Gynecologic Cancer

Treatments

Combination Product: Musculoskeletal health package

Study type

Interventional

Funder types

Other

Identifiers

NCT04555317
CFTSp180

Details and patient eligibility

About

A randomised controlled clinical feasibility trial to determine the feasibility and acceptability of a "musculoskeletal health package (MHP)" intervention in women undergoing pelvic radiotherapy for gynaecological malignancies and inform power calculations for a definitive trial.

Enrollment

80 estimated patients

Sex

Female

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • age over 18 years
  • histologically confirmed uterine or cervix cancer
  • patients undergoing potentially curative/adjuvant radiotherapy
  • ability to give informed consent to participate

Exclusion criteria

  • age less than 18 years or greater than 85 years
  • patients with pre-existing bone conditions such as: osteoporosis treated with bisphosphonates in the previous 5 years/fibrous dysplasia/osteogenesis imperfecta or other metabolic bone condition
  • inability to give informed consent to participate
  • home address outside Greater Manchester
  • contraindication or intolerance of Magnetic Resonance scanning

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

80 participants in 2 patient groups

Standard of Care
No Intervention group
Description:
No intervention. Standard of care cancer pathway followed.
Musculoskeletal Health Package
Active Comparator group
Description:
3 month prehabilitation exercise program during radiotherapy and assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))
Treatment:
Combination Product: Musculoskeletal health package

Trial contacts and locations

1

Loading...

Central trial contact

Louise James; Claire Higham

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems